Inflammation - Pipeline Review, H1 2014

Inflammation - Pipeline Review, H1 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Inflammation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammation and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Inflammation

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 

- The report reviews key players involved in the therapeutics development for Inflammation and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Inflammation pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Inflammation

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Inflammation pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. Amgen Inc. Questcor Pharmaceuticals, Inc. GlaxoSmithKline plc Genentech, Inc. Nektar Therapeutics Agenus, Inc. MedImmune, LLC Gilead Sciences, Inc. Daiichi Sankyo Company, Limited Merck & Co., Inc. Ablynx NV Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Euroscreen S.A. Novo Nordisk A/S Infinity Pharmaceuticals, Inc. Reliance Life Sciences Pvt. Ltd. Piramal Enterprises Limited Amorepacific Corporation Astellas Pharma Inc. Kowa Company, Ltd. LEO Pharma A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Teva Pharmaceutical Industries Limited UCB S.A. Zydus Cadila Healthcare Limited Exelixis, Inc. Celgene Corporation Bayer AG Incyte Corporation Merck KGaA Evotec AG Harbor Therapeutics, Inc. Momenta Pharmaceuticals, Inc. Star Scientific, Inc. Genfit SA Can-Fite BioPharma Ltd. Karo Bio AB Ligand Pharmaceuticals, Inc. TG Therapeutics, Inc. Lpath, Inc. Lupin Limited Basilea Pharmaceutica AG NicOx S.A. Compugen Ltd. Orchid Chemicals & Pharmaceuticals Ltd Palatin Technologies, Inc. Pharmaxis Limited Alexion Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. CSL Limited Cytomedix, Inc. Array BioPharma Inc. Dynavax Technologies Corporation XOMA Corporation MorphoSys AG BioInvent International AB Transgene SA Progen Pharmaceuticals Limited JW Pharmaceutical Corporation Galectin Therapeutics, Inc. Ahn-Gook Pharmaceutical Co., Ltd. Biotie Therapies Corp. LTT Bio-Pharma Co., Ltd. Galapagos NV Synta Pharmaceuticals Corp. BioAlliance Pharma SA Innate Pharma SA MetrioPharm AG Proteo, Inc. Verona Pharma Plc Angelini Group Affitech A/S Debiopharm International S.A. Chroma Therapeutics Ltd. Advinus Therapeutics Ltd. CJ CheilJedang Corp. Antitope Ltd. Axxam SpA INSYS Therapeutics, Inc. Aurigene Discovery Technologies Limited Alba Therapeutics Corporation AcurePharma AB Ambit Biosciences Corporation Viron Therapeutics, Inc. Immupharma Plc Upsher-Smith Laboratories, Inc. Molecular Partners AG Physica Pharma Acceleron Pharma, Inc. Lipicard Technologies Limited Conaris Research Institute AG Hutchison MediPharma Limited Affibody AB Ache Laboratorios Farmaceuticos S/A Aquinox Pharmaceuticals Inc. Argos Therapeutics, Inc. Aegera Therapeutics Inc. Anchor Therapeutics, Inc. AnaptysBio, Inc. Allozyne, Inc. Funxional Therapeutics Ltd Oxagen Limited CompleGen, Inc. Catabasis Pharmaceuticals, Inc. Ambrx, Inc. PLx Pharma Inc. Five Prime Therapeutics, Inc. Vaccinex, Inc. ProNAi Therapeutics, Inc. Vascular Biogenics Ltd. AIM Therapeutics Inc. NovImmune SA TxCell SA Endocyte, Inc. Selexys Pharmaceuticals Corporation CG Pharmaceuticals, Inc. Siena Biotech S.p.A. Polyphor Ltd. Noxxon Pharma AG Atox Bio Inc. Rimonyx Pharmaceuticals Ltd. Karus Therapeutics Limited Omeros Corporation Sosei Co. Ltd. Bridge Bioresearch Plc Enceladus Pharmaceuticals BV Targacept, Inc. ChemoCentryx, Inc. Tobira Therapeutics, Inc. Vitae Pharmaceuticals, Inc. Resolvyx Pharmaceuticals, Inc arGEN-X BV Kyorin Pharmaceutical Co., Ltd. Nuevolution A/S Laboratorios LETI S.L. GlycoMimetics, Inc. Lipopharma Therapeutics SL Vicus Therapeutics, LLC Medisyn Technologies, Inc. Ensemble Discovery Corporation Medestea Research & Production S.p.A. Encore Therapeutics Inc. Gem Pharmaceuticals, LLC CoDa Therapeutics, Inc. Bial - Portela & Ca, S.A. Adocia Sorrento Therapeutics, Inc. Covagen AG Zymeworks Inc. aTyr Pharma, Inc. Protagonist Therapeutics Inc. Lycera Corp. PharmAbcine, Inc. UNIZYME Laboratories A/S Interprotein Corporation Heptares Therapeutics Ltd. Signum Biosciences, Inc. Zyngenia, Inc. ISU ABXIS Co.,Ltd. Pepscan Therapeutics Faron Pharmaceuticals Oy SelectX Pharmaceuticals, Inc. Sirona Biochem Corp Cellmid Limited Fibrocell Science, Inc. Mirrx Therapeutics A/S Biolab Sanus Farmaceutica Ltda. Vichem Chemie Research Ltd. XBiotech USA, Inc. ImQuest Life Sciences PharmaIN Corporation CellAct Pharma GmbH Serodus ASA CytomX Therapeutics, Inc. Celtaxsys, Inc. InflaRx GmbH National Pharmaceutical Corp. TPP Global Development Ltd Sphaera Pharma Pvt. Ltd. APT Therapeutics, Inc. Complix NV Cytoguide ApS VivaCell Biotechnology Espana S.L. Karyopharm Therapeutics, Inc. Apexigen, Inc. centrose llc Ajinomoto Pharmaceuticals Co., Ltd. . X-BODY BioSciences, Inc. Lead Discovery Center GmbH Enlivex Therapeutics Ltd SciFluor Life Sciences, LLC Visionary Pharmaceuticals, Inc. Allinky Biopharma Creabilis SA ARA Healthcare Pvt. Ltd. XImmune AB Kadmon Corporation, LLC PIQUR Therapeutics AG Humabs BioMed SA Istituto Italiano di Tecnologia LondonPharma Ltd AbbVie Inc. Curadev Pharma Private Limited TechnoPhage SA ChironWells GmbH Vipergen ApS Pharmedartis GmbH XL-protein GmbH Ziarco Pharma Ltd Netherlands Translational Research Center B.V. Allakos Inc. Arachos Pharma Ltd. Thelial Technologies S.A. MI.TO. Technology S.r.L. Dong-A Socio Group Iltoo Pharma Debiopharm Group

To view the table of contents and know more details please visit Inflammation - Pipeline Review, H1 2014